Floatz logo

Aripiprazole Lauroxil

Schizophreniform Disorder

University of California, Los AngelesSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Schizophreniform Disorder cohort.

Asset / SponsorPhaseRating
Raloxifene
Iris Sommer
Phase 4A
Olanzapine
Alkermes, Inc.
Phase 4A
Bxcl501
BioXcel Therapeutics Inc
Phase 4A
N-Acetyl-L-Cysteine
University of Maryland, Baltimore
Phase 4BBB
Risperdal
Northwell Health
Phase 4BBB

View all 41 →

Same molecule, other indications

Aripiprazole Lauroxil is also rated in:

schizophreniaDormant
BB
Indicative ·
66 / 100
View asset →
schizoaffective depressive disorderDormant
B
Indicative ·
62 / 100
View asset →
schizoaffective disorderDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →